The authors discuss contributing factors that distinguish subsets of patients with glioma who may benefit from immune checkpoint blockade.
[Journal Of Clinical Investigation]
Home Newsletters Neural Cell News Immune Checkpoint Blockade in Glioblastoma: From Tumor Heterogeneity to Personalized Treatment
